British Association of Dermatologists Guidelines for Biologic Therapy for Psoriasis 2017

C.H. Smith; Z.K. Jabbar-Lopez; Z.Z. Yiu; T. Bale; A.D. Burden; L.C. Coates; M. Cruickshank; T. Hadoke; E. MacMahon; R. Murphy; C. Nelson-Piercy; C.M. Owen; R. Parslew; E. Peleva; E. Pottinger; E.J. Samarasekera; J. Stoddart; C. Strudwicke; V. A. Venning; R.B. Warren; L.S. Exton; M.F. Mohd Mustapa

Disclosures

The British Journal of Dermatology. 2017;177(3):628-636. 

In This Article

Purpose and Scope of the Guideline

The overall aim of the guideline is to provide evidence-based recommendations on the use of biologic therapies (adalimumab, etanercept, infliximab, ixekizumab, secukinumab and ustekinumab) in adults, children and young people for the treatment of psoriasis; consideration is given to the specific needs of people with psoriasis and psoriatic arthritis. Biologic therapies have now been in use for over 10 years, and with accrued patient-year exposure and clinical experience, many areas that were covered in previous versions of the guideline are now part of the summary of product characteristics (SPC) and/or routine care so that specific recommendations are redundant. Therefore, in this update we focus on areas where there has been a major change in the evidence base or clinical practice, where practice is very varied and/or where clear recommendations are lacking.

This set of guidelines has been developed using the British Association of Dermatologists (BAD) recommended methodology[1] with reference to the Appraisal of Guidelines Research and Evaluation (AGREE II) instrument (www.agreetrust.org)[2] and the Grading of Recommendations Assessment, Development and Evaluation (GRADE).[3] The recommendations were developed for implementation in the National Health Service (NHS) in the U.K. Note that the guideline recommendations will normally fall within licensed indications; exceptionally, and only if clearly supported by evidence, use outside a licensed indication may be recommended. The guideline assumes that prescribers cross-reference a drug's SPC to inform clinical decision making for individual patients. Where relevant, this guidance applies to biosimilars (similar biological medical products), subject to recommendations given within the BAD position statement[4] and the European Medicines Agency guidelines.[5] This guidance does not cover agents licensed outside the U.K. or use of biologic therapies for indications other than psoriasis or use when psoriatic arthritis is the main indication.

Comments

3090D553-9492-4563-8681-AD288FA52ACE

processing....